ClinicalTrials.gg
Active, not recruitingNCT05681351Updated Dec 1, 2025

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

A Phase 3 interventional study of Olezarsen in Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals, Inc.. Active, not recruiting at 262 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
885
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Hypertriglyceridemia · Ionis Pharmaceuticals, Inc..

Enrollment
2nd of 12
885 · median 114
Started
2022
with 3 others
Phase 3
5 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., this one is the 2nd largest by enrollment, is one of 4 that started in 2022, is one of 5 in phase 3, and was the 11th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

1 of the 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc. is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypertriglyceridemia by Ionis Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Read the detailed description

This is a multi-center, open-label extension (OLE) study of approximately 800 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 157-week treatment period. The study will include a 31-day qualification Period, a 157-week treatment period, and a 13-week post-treatment period.

03

Conditions studied

  • Severe Hypertriglyceridemia

Browse trials for

Keywords

  • ISIS 678354
  • Olezarsen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Satisfactory completion of either ISIS 678354-CS5 or ISIS 678354-CS6 with an acceptable safety profile, per Investigator judgment. Satisfactory completion requires that the patient did not terminate early from treatment.
  • Participants must be on a stable regimen of lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. A patient may be eligible if their regimen of lipid-lowering therapy has been changed recently, provided that lipid lowering medications are optimized and stabilized for at least 4 weeks prior to the end of the Qualification Period of this OLE study; ideally, such changes are initiated after Week 53 of the index study (ISIS 678354-CS5 or CS6).
  • A patient may re-enroll in the study after having completed the study when the Treatment Period was 53 weeks, if the patient satisfactorily completed the study with an acceptable safety profile, per Investigator judgment. In the case of re-enrollment, there is no limit on the time gap between completion of treatment under the previous protocol and dosing upon re-enrollment (i.e., may exceed 17 weeks between doses).

Key Exclusion Criteria:

  • Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study, including need for treatment with disallowed medications, or need to change the required stable regimen as per either ISIS 678354-CS5 or ISIS 678354-CS6 study entry criteria. It is acceptable to adjust a regimen of lipid-lowering therapy as described in the second Key Inclusion Criterion above, and it is acceptable to adjust or stop lipid-lowering therapy at or after Week 13 per Investigator judgment.

NOTE: Other Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
885 participants (actual)

Study arms

  • Experimental
    Olezarsen

    Participants who completed either ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326) study would be enrolled to receive olezarsen, subcutaneous (SC) injection, once every 4 weeks from Week 1 through Week 153.

    Drug: Olezarsen

Interventions

  • Administered as SC injection.

    Also known as: AKCEA-APOCIII-LRx, ISIS 678354

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Change in Clinical Laboratory Values From Baseline to Week 53, From Baseline to Week 105, and From Baseline to Week 157

    Time frame: Baseline up to Week 157

  2. Proportion of Participants Who Experience Adverse Events (AEs)

    Time frame: Baseline up to Week 157

  3. Proportion of Participants Who Use Concomitant Medications

    Time frame: Baseline up to Week 157

07

Study locations

262 sites

Showing the first 100 of 262 sites across 33 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Mar 2027, 51 months after the start.

Of 28 industry-sponsored phase 3 interventional studies under Hypertriglyceridemia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 31. This study's planned 51 months is above that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 18 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2022
First posted
Jan 12, 2023
StartActual
Dec 13, 2022
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05681351
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Dec 13, 2022
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Dec 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olezarsen

Start the discussion